Patents Assigned to TRISKEL THERAPEUTICS B.V
  • CYTOKINE DESIGN
    Publication number: 20110200552
    Abstract: The present invention relates to novel cytokines, which have a modified selectivity/specificity for their cognate receptors. In particular, the invention relates to a variant TRAIL protein, which has superior selectivity for the death receptor 4 (TRAIL-RI) over the death receptor 5 (TRAIL-R2). In addition, the invention relates to a variant TRAIL protein which exhibits superior selectivity for the death receptor 4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4).
    Type: Application
    Filed: November 21, 2008
    Publication date: August 18, 2011
    Applicants: RIJKSUNIVERSITEIT GRONINGEN, NATIONAL UNIVERSITY OF IRELAND, GALWAY, TRISKEL THERAPEUTICS B.V, Fundacio Privada Centre De Regulacio Genomica (CRG), Institucio Catalana De Recerca I Estudis Avancats (ICREA)
    Inventors: Carlos Ricardo Rodrigues Dos Reis, Wilhelmus Johannes Quax, Afshin Samali, Eva Szegezdi, Robbert Hans Cool, Albert Martinus Van Der Sloot, Luis Serrano, Vicente Tur